Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Pharmacy Bodies Work Together To Promote The Integration Of Pharmacy Within Lord Darzi's Primary & Community Care Strategy
"Maximising Health Gain Through Community Pharmacy" is the title of two jointly badged publications from pharmacy organisations CCA, NPA, RPSGB, PSNC and AIMp. The documents, which were produced in collaboration with the NHS Alliance, were launched to the NHS this week, as part of a strategy to promote the role of pharmacists to commissioners, managers, general practitioners and others in primary care. The documents also seek to influence the commissioning of pharmacy services by PCTs under World Class Commissioning and the integration of pharmacy into Practice Based Commissioning (PBC).

Diabetes Drug Shows MS Potential
A small trial testing the benefits in multiple sclerosis (MS) of a drug used to treat type II diabetes, in combination with beta-interferon-1a, has been shown to potentially prevent brain cell loss.
News of the day
MacroGenics And Lilly Achieve Targeted Patient Enrollment In PROTEGE, A Global Phase 2/3 Clinical Trial Of Teplizumab In Type 1 Diabetes
MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) announced that the PROTEGE trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under development for the treatment of individuals with recent-onset type 1 diabetes.
Public Health

Mesoblast Announce Heart Muscle Function Improved After Single, Lowest-Dose Injection Of "Off-The-Shelf" Stem Cells In Patients With Heart Failure

Australia"s regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced positive three-month interim efficacy results from the first 20 patients enrolled in the Phase 2 heart failure trial of the proprietary allogeneic, or "off-the-shelf", adult stem cell product Revascor(TM). Three months after receiving a single injection into damaged heart muscle of the lowest dose of Revascor(TM), patients with moderate-severe congestive heart failure demonstrated significantly improved heart muscle function. The randomised, placebo-controlled Phase 2 trial is being run at multiple centres in the United States by Mesoblast"s United States-based associated company Angioblast Systems Inc. The trial aims to compar! e one of three increasing doses of Revascor(TM) against standa! rd of ca re in up to 60 patients suffering from moderate-severe congestive heart failure, defined as a baseline ejection fraction (EF) 40% or lower by echocardiogram. On the basis of the positive interim efficacy results and the excellent safety profile seen to date in the first group of patients receiving the lowest dose of Revascor(TM), the second group of patients set to receive the next higher dose is currently in active recruitment. In the first 20-patient cohort, 15 were randomised to receive the lowest dose of Revascor(TM) and 5 were randomised to the control arm. While control patients with baseline EF 40 or below demonstrated an 11% mean decrease in EF over the first 3 months (mean EF values decreased from 31 to 27), patients with baseline EF 40 or below who received a single injection into damaged heart muscle of the lowest dose of Revascor(TM) showed a 37% mean increase in EF over this period (mean EF increased from 28 to 37, p=0.017). The 10-point me! an difference in absolute EF at three months between cell-treated and control patients was significant (pMesoblast Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009